Maintenance Of The Response To Sacral Pulsed Radiofrequency In Chronic Prostatitis/Pelvic Pain Syndrome Using Hyperbaric Oxygen
|Gallego-Vilar D*, Cuñat Albert E and Gallego-Gomez J|
|Departament of Urology, Hospital General Universitario de Castellon, Castellon de la Plana, Valencia, Spain|
|Corresponding Author :||Daniel Gallego-Vilar
Department of Urology
Hospital General Universitario de Castellon
Castellon de la Plana, Valencia, Spain
E-mail: [email protected]
|Received November 19, 2013; Accepted January 15, 2014; Published January 17, 2014|
|Citation: Gallego-Vilar D, Cuñat Albert E, Gallego-Gomez J (2014) Maintenance of the Response to Sacral Pulsed Radiofrequency in Chronic Prostatitis/Pelvic Pain Syndrome using Hyperbaric Oxygen. J Pain Relief 3:131. doi: 10.4172/2167-0846.1000131|
|Copyright: © 2014 Gallego-Vilar D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Introduction: None of treatments reported for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has shown considerable improvement in patient´s daily life. Our objective is to determine the efficacy of hyperbaric oxygen therapy (HBOT) in the maintenance of response after sacral pulsed radiofrequency (PRF) in patients with CP/CPPS.
Material and methods: Prospective, comparative study including men with CP/CPPS divided in group A: S2-S4 PRF; and group B: S2-S4 PRF+HBO. The evaluated variables were pain (through the visual analog scale, VAS), and quality of life using the The NIH Chronic Prostatitis Symptom Index (CPSI) at 0, 1, 3, 6 and 12 months-follow up. Responders were predefined as patients who had experienced a more than 50% of decrease in the total NIH- CPSI score and more than 50% improvement in different areas of KHQ.
Results: 24 patients met the inclusion/exclusion criteria (17 Group A; 7 Group B) . A significant manteinance of improvement (p<0.05) for pain subscore, urinary subscore, quality of life subscore, total NIH-CPSI score and all the areas of KHQ was noticed in Group B after 18 months follow-up. No adverse effects were reported.
Conclusions: In this study, HBO improved the maintenance of the beneficial effects of sacral PRF among men with CP/CPPS.